Clinical Products
This site is for Healthcare Professionals only
Latest News Headlines
- NEW Anti-Gliadin (Modified Gliadin Peptide) EIA28 August 2008
- First myeloma kidney patient recruited onto EuLITE clinical trial09 June 2008
- Biennial 2008 - Serum Free Light Chain Symposium14 May 2008
- New Infectious Disease ELISA assays21 April 2008
- New Cystatin C assay for Roche Modular P18 March 2008
- Independent Review discusses Value of Serum Free Light Chain Assays11 February 2008
Binding Site specialises in the research, development and manufacture of innovative, high quality, immunodiagnostic assays in the fields of autoimmune disease, multiple myeloma (and other B cell disorders) and investigation of the immune response. World-wide customer support is provided from Binding Site offices in the UK (head office), USA, Germany, France and Spain, and by an extensive network of experienced distributor companies.
Latest News 28 August 2008
NEW Anti-Gliadin (Modified Gliadin Peptide) EIA
These 
assays are highly sensitive and specific for the measurement of human serum IgG and IgA antibodies against a modified gliadin peptide (MGP), as an aid in the diagnosis and monitoring of coeliac disease.
- More sensitive and specific than traditional assays that use a gliadin extract antigen preparation
- All assays can be used for screening or semi quantitative measurement of antibodies
- IgG, IgA or Combi kit formats available
- Validated protocols for DSX and DS2 automated systems More
.jpg)